Borderline Ovarian Serous Tumor: Clinical Trials

3 trials for Borderline Ovarian Serous Tumor, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed. 2 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 22Completed 2
Phase 31Completed 1

Follow Borderline Ovarian Serous Tumor: new trials by email Literature Review of Borderline Ovarian Serous Tumor trials Research Report on Borderline Ovarian Serous Tumor

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
Letrozole, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride - Borderline Ovarian Serous Tumor, Micropapillary Serous Carcinoma
Phase 2 / Phase 3CompletedNational Cancer Institute (NCI)2602014-04-112026-08-04
Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer
Laboratory Biomarker Analysis, Pharmacological Study, Selumetinib - Borderline Ovarian Serous Tumor, Low Grade Ovarian Serous Adenocarcinoma
Phase 2CompletedNational Cancer Institute (NCI)522007-12-172020-12-03
Collecting Tumor Samples From Patients With Gynecological Tumors
Laboratory Biomarker Analysis - Borderline Ovarian Clear Cell Tumor, Borderline Ovarian Serous Tumor
CompletedGynecologic Oncology Group2751992-06-012016-10-28

Narrower conditions

Cystadenocarcinoma, Serous (2)  ·  Brenner Tumor (1)  ·  Fallopian Tube Neoplasms (1)  ·  Gestational Trophoblastic Disease (1)  ·  Melanoma (1)  ·  Mesothelioma, Malignant (1)  ·  Ovarian Germ Cell Cancer (1)  ·  Ovarian Neoplasms (1)  ·  Sarcoma, Endometrial Stromal (1)  ·  Uterine Cervical Neoplasms (1)  ·  Vaginal Neoplasms (1)  ·  Vulvar Neoplasms (1)

Broader conditions

Neoplasms (3)  ·  Neoplasms by Histologic Type (3)  ·  Neoplasms, Glandular and Epithelial (3)  ·  Adenocarcinoma (2)  ·  Carcinoma (2)  ·  Cystadenocarcinoma (2)  ·  Neoplasms, Cystic, Mucinous, and Serous (2)  ·  Adenoma (1)  ·  Adnexal Diseases (1)  ·  Endocrine Gland Neoplasms (1)  ·  Endocrine System Diseases (1)  ·  Endometrial Neoplasms (1)  ·  Endometrial Stromal Tumors (1)  ·  Fallopian Tube Diseases (1)  ·  Female Urogenital Diseases (1)

Interventions

AZD 6244 (1)  ·  Doxorubicin (1)  ·  Letrozole (1)  ·  Paclitaxel (1)  ·  Tamoxifen (1)  ·  Taxes (1)  ·  Topotecan (1)  ·  liposomal doxorubicin (1)  ·  trametinib (1)

Sponsors

National Cancer Institute (NCI) (2)  ·  Gynecologic Oncology Group (1)

Countries

United States (3)  ·  United Kingdom (1)

Top investigators

David M Gershenson (1)  ·  John H Farley (1)  ·  Michael Cibull (1)

Results publications

PMID 23261356, PMID 35123694

NIH funding

U10CA180868 (3), P50CA083639 (1), U10CA027469 (1)